Our KDG and TF discoveries generate new clues to understanding RA pathogenesis, and potential new targets towards developing different types of cells-specific treatment, such as targeting the FLS to maximize disease control in a patient with partial response to an anti-TNF and JAK inhibitor therapy. Here, TF is linked to rheumatoid arthritis.